Elanco Animal Health Inc
NYSE:ELAN

Watchlist Manager
Elanco Animal Health Inc Logo
Elanco Animal Health Inc
NYSE:ELAN
Watchlist
Price: 13.13 USD -1.94% Market Closed
Market Cap: 6.5B USD
Have any thoughts about
Elanco Animal Health Inc?
Write Note

Elanco Animal Health Inc
Cost of Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Elanco Animal Health Inc
Cost of Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cost of Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Elanco Animal Health Inc
NYSE:ELAN
Cost of Revenue
-$2B
CAGR 3-Years
3%
CAGR 5-Years
-7%
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Cost of Revenue
-$27B
CAGR 3-Years
3%
CAGR 5-Years
0%
CAGR 10-Years
-2%
Bristol-Myers Squibb Co
NYSE:BMY
Cost of Revenue
-$11.4B
CAGR 3-Years
-6%
CAGR 5-Years
-10%
CAGR 10-Years
-11%
Pfizer Inc
NYSE:PFE
Cost of Revenue
-$17.5B
CAGR 3-Years
10%
CAGR 5-Years
N/A
CAGR 10-Years
-6%
Merck & Co Inc
NYSE:MRK
Cost of Revenue
-$14.8B
CAGR 3-Years
-2%
CAGR 5-Years
-2%
CAGR 10-Years
2%
Eli Lilly and Co
NYSE:LLY
Cost of Revenue
-$7.8B
CAGR 3-Years
-4%
CAGR 5-Years
-11%
CAGR 10-Years
-4%
No Stocks Found

Elanco Animal Health Inc
Glance View

Market Cap
6.5B USD
Industry
Pharmaceuticals

Elanco Animal Health Inc. has emerged as a leading player in the global animal health industry, driven by a commitment to improving the health and productivity of livestock and pets alike. With a history that dates back to the late 1950s, Elanco operates under the guiding principle that healthy animals lead to healthy societies, making their mission not just a business goal but a moral imperative. The company's expansive portfolio includes vaccines, parasiticides, antibiotics, and nutritional products, which cater to a diverse range of species including cattle, pigs, and companion animals. By leveraging cutting-edge research and development, Elanco continually innovates to address emerging challenges in animal health, such as antibiotic resistance and the demand for sustainable farming practices, thereby aligning itself with broader societal health agendas. For investors, Elanco presents a compelling opportunity anchored in robust financial performance and a resilient business model. The company's strategic acquisitions have bolstered its market presence, particularly following the acquisition of Bayer’s Animal Health business, which significantly expanded its product offerings and revenue base. Additionally, Elanco has demonstrated strong growth potential, driven by increasing global demand for protein and the human-animal bond that fuels spending on pet care. With a seasoned management team and a focus on sustainability and innovation, Elanco is well-positioned to capitalize on market trends while delivering value to shareholders. As the world navigates the complexities of food security and animal welfare, Elanco stands out as both a growth story and a responsible investment in the future of health.

ELAN Intrinsic Value
19.36 USD
Undervaluation 32%
Intrinsic Value
Price

See Also

What is Elanco Animal Health Inc's Cost of Revenue?
Cost of Revenue
-2B USD

Based on the financial report for Sep 30, 2024, Elanco Animal Health Inc's Cost of Revenue amounts to -2B USD.

What is Elanco Animal Health Inc's Cost of Revenue growth rate?
Cost of Revenue CAGR 5Y
-7%

Over the last year, the Cost of Revenue growth was -8%. The average annual Cost of Revenue growth rates for Elanco Animal Health Inc have been 3% over the past three years , -7% over the past five years .

Back to Top